Alexandra Collins

Dr. Alexandra Collins

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
SMSamara Mayer
Samara Mayer
JBJade Boyd
Jade Boyd
ACAlexandra Collins
Alexandra Collins
MKMary Clare Kennedy
Mary Clare Kennedy
NFNadia Fairbairn
Nadia Fairbairn
RMRyan McNeil
Ryan McNeil

1 January 2017 in International Journal of Drug Policy
Verified
Journal Article
Closed access
ACAlexandra Collins
Alexandra Collins
CSCarol Strike
Carol Strike
AGAdrian Guta
Adrian Guta
RTRosalind Baltzer Turje
Rosalind Baltzer Turje
PMPatrick McDougall
Patrick McDougall
RMRyan McNeil
Ryan McNeil

1 June 2017 in The Lancet HIV
Verified
Journal Article
Closed access
RHRobert S Hogg
Robert S Hogg
OEOghenowede Eyawo
Oghenowede Eyawo
ACAlexandra Collins
Alexandra Collins
WZWendy Zhang
Wendy Zhang
SJShahab Jabbari
Shahab Jabbari
JMJulio S G Montaner
Julio S G Montaner

1 February 2020 in International Journal of Drug Policy
Verified
Journal Article
Closed access
ACAlexandra Collins
Alexandra Collins
JBJade Boyd
Jade Boyd
KHKanna Hayashi
Kanna Hayashi
HCHannah L.F. Cooper
Hannah L.F. Cooper
SGShira Goldenberg
Shira Goldenberg
RMRyan McNeil
Ryan McNeil

1 July 2019 in International Journal of Drug Policy
Verified
Journal Article
Closed access
ACAlexandra Collins
Alexandra Collins
GBGeoff Bardwell
Geoff Bardwell
RMRyan McNeil
Ryan McNeil
JBJade Boyd
Jade Boyd

6 December 2017 in Harm Reduction Journal
Verified
Journal Article
Open access
PDF file
GBGeoff Bardwell
Geoff Bardwell
ACAlexandra Collins
Alexandra Collins
RMRyan McNeil
Ryan McNeil
JBJade Boyd
Jade Boyd
North America is currently experiencing an overdose epidemic due to a significant increase of fentanyl-adulterated opioids and related analogs. Multiple jurisdictions have declared a public health emergency given the increasing number of overdose deaths. In the province of British Columbia (BC) in Canada, people who use drugs and who are unstably housed are disproportionately affected by a rising overdose crisis, with close to 90% of overdose deaths occurring indoors. Despite this alarming number, overdose prevention and response interventions have yet to be widely implemented in a range of housing settings. There are few examples of overdose prevention interventions in housing environments. In BC, for example, there are peer-led naloxone training and distribution programs targeted at some housing environments. There are also “supervised” spaces such as overdose prevention sites (similar to supervised consumption sites (SCS)) located in some housing environments; however, their coverage remains limited and the impacts of these programs are unclear due to the lack of evaluation work undertaken to date. A small number of SCS exist globally in housing environments (e.g., Germany), but like overdose prevention sites in BC, little is known about the design or effectiveness, as they remain under-evaluated. Implementing SCS and other overdose prevention interventions across a range of housing sites provides multiple opportunities to address overdose risk and drug-related harms for marginalized people who use drugs. Given the current overdose crisis rising across North America, and the growing evidence of the relationship between housing and overdose, the continued implementation and evaluation of novel overdose prevention interventions in housing environments should be a public health priority. A failure to do so will simply perpetuate what has proven to be a devastating epidemic of preventable death.